References
[1] A. M. Schmidt. (2018). “Highlighting Diabetes Mellitus: The Epidemic Continues.” Arterioscler Thromb Vasc Biol., vol. 38, no. 1, pp. e1-e8, 2018.
[2] A. American Diabetes. (2015). “(2) Classification and diagnosis of diabetes.” Diabetes Care, vol. 38, Suppl, pp. S8-S16, 2015.
[3] P. Zimmet, K. G. Alberti, D. J. Magliano, and P. H. Bennett. (2016). “Diabetes mellitus statistics on prevalence and mortality: facts and fallacies.” Nat Rev Endocrinol, vol. 12, no. 10, pp. 616-622, 2016.
[4] K. T. Kao and M. A. Sabin. (2016). “Type 2 diabetes mellitus in children and adolescents.” Aust Fam Physician, vol. 45, no. 6, pp. 401-406, 2016.
[5] Y. Zheng, S. H. Ley, and F. B. Hu. (2018). “Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.” Nat Rev Endocrinol, vol. 14, no. 2, pp. 88-98, 2018.
[6] M. Hanefeld, H. Fleischmann, T. Siegmund, and J. Seufert. (2020). “Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update.” Diabetes Ther, vol. 11, no. 8, pp. 1645-1666, 2020.
[7] D. R. Owens. (2013). “Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes.” Diabetes Technol Ther, vol. 15, no. 9, pp. 776-785, 2013.
[8] S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. L. Peters, A. Tsapas, R. Wender, and D. R. Matthews. (2012). “Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetologia, vol. 55, no. 6, pp. 1577-1596, 2012.
[9] C. L. Morgan, C. D. Poole, M. Evans, A. H. Barnett, S. Jenkins-Jones, and C. J. Currie. (2012). “What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes.” J Clin En-docrinol Metab, vol. 97, no. 12, pp. 4605-4612, 2012.
[10] M. Ridderstrale, K. R. Andersen, C. Zeller, G. Kim, H. J. Woerle, U. C. Broedl, and E.-R. H. H. S. T. Investigators. (2014). “Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.” Lancet Diabetes Endocrinol, vol. 2, no. 9, pp. 691-700, 2014.
[11] M. Nauck. (2016). “Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.” Diabetes Obes Metab, vol. 18, no. 3, pp. 203-216, 2016.
[12] S. P. Marso, G. H. Daniels, K. Brown-Frandsen, P. Kristensen, J. F. Mann, M. A. Nauck, S. E. Nissen, S. Pocock, N. R. Poulter, L. S. Ravn, W. M. Steinberg, M. Stockner, B. Zinman, R. M. Bergenstal, J. B. Buse, L. S. Committee, and L. T. Investigators. (2016). “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.” N Engl J Med., vol. 375, no. 4, pp. 311-322, 2016.
[13] N. Rachdaoui. (2020). “Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus.” Int J Mol Sci., vol. 21, no. 5, 2020.
[14] F. A. M. Al-Omary. (2017). “Gliclazide.” Profiles Drug Subst Excip Relat Methodol, vol. 42, pp. 125-192, 2017.
[15] W. A. Nuffer and J. M. Trujillo. (2015). “Liraglutide: A New Option for the Treatment of Obesity.” Pharmacotherapy, vol. 35, no. 10, pp. 926-934, 2015.
[16] P. M. O'Neil, A. L. Birkenfeld, B. McGowan, O. Mosenzon, S. D. Pedersen, S. Wharton, C. G. Carson, C. H. Jepsen, M. Kabisch, and J. P. H. Wilding. (2018). “Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.” Lancet, vol. 392, no. 10148, pp. 637-649, 2018.
[17] C. Tzanetakos, A. Melidonis, C. Verras, G. Kourlaba, and N. Maniadakis. “Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin or Exenatide in Patients With Inadequately Controlled Type 2 Diabetes On Oral Antidiabetic Drugs In Greece.” Value Health, vol. 17, no. 7, p. A345, 2014.
[18] N. Peradze, O. M. Farr, N. Perakakis, I. Lazaro, A. Sala-Vila, and C. S. Mantzoros. (2019). “Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.” Cardiovasc Diabetol, vol. 18, no. 1, p. 141, 2019.
[19] Y. R. Wu, X. Y. Shi, C. Y. Ma, Y. Zhang, R. X. Xu, and J. J. Li. (2019). “Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.” Cardiovasc Diabetol, vol. 18, no. 1, p. 146, 2019.
[20] M. Fan, H. Jiang, Y. Zhang, Y. Ma, L. Li, and J. Wu. (2018). “Liraglutide Enhances Autophagy and Promotes Pancreatic beta Cell Proliferation to Ameliorate Type 2 Diabetes in High-Fat-Fed and Streptozotocin-Treated Mice.” Med Sci Monit, vol. 24, pp. 2310-2316, 2018.
[21] M. Li, Y. Yang, D. Jiang, M. Ying, Y. Wang, and R. Zhao. (2017). “Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.” Medicine (Baltimore), vol. 96, no. 39, p. e8161, 2017.